Pathogenic epitopes, heterologous immunity and vaccine design

Substantial research has been directed towards the development of a new generation of vaccines that are based on the inclusion of immunogenic epitopes in recombinant vectors. Here we examine the evidence that under certain conditions immunogenic epitopes can do more harm than good and might therefor...

Descripción completa

Detalles Bibliográficos
Autores principales: Welsh, Raymond M., Fujinami, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2007
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097378/
https://www.ncbi.nlm.nih.gov/pubmed/17558423
http://dx.doi.org/10.1038/nrmicro1709
_version_ 1783510994136334336
author Welsh, Raymond M.
Fujinami, Robert S.
author_facet Welsh, Raymond M.
Fujinami, Robert S.
author_sort Welsh, Raymond M.
collection PubMed
description Substantial research has been directed towards the development of a new generation of vaccines that are based on the inclusion of immunogenic epitopes in recombinant vectors. Here we examine the evidence that under certain conditions immunogenic epitopes can do more harm than good and might therefore be considered pathogenic. We suggest that the specific removal of such pathogenic epitopes from vaccines might increase their prophylactic potential, while minimizing the risk of side-effects from vaccine use.
format Online
Article
Text
id pubmed-7097378
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70973782020-03-26 Pathogenic epitopes, heterologous immunity and vaccine design Welsh, Raymond M. Fujinami, Robert S. Nat Rev Microbiol Article Substantial research has been directed towards the development of a new generation of vaccines that are based on the inclusion of immunogenic epitopes in recombinant vectors. Here we examine the evidence that under certain conditions immunogenic epitopes can do more harm than good and might therefore be considered pathogenic. We suggest that the specific removal of such pathogenic epitopes from vaccines might increase their prophylactic potential, while minimizing the risk of side-effects from vaccine use. Nature Publishing Group UK 2007 /pmc/articles/PMC7097378/ /pubmed/17558423 http://dx.doi.org/10.1038/nrmicro1709 Text en © Nature Publishing Group 2007 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Welsh, Raymond M.
Fujinami, Robert S.
Pathogenic epitopes, heterologous immunity and vaccine design
title Pathogenic epitopes, heterologous immunity and vaccine design
title_full Pathogenic epitopes, heterologous immunity and vaccine design
title_fullStr Pathogenic epitopes, heterologous immunity and vaccine design
title_full_unstemmed Pathogenic epitopes, heterologous immunity and vaccine design
title_short Pathogenic epitopes, heterologous immunity and vaccine design
title_sort pathogenic epitopes, heterologous immunity and vaccine design
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097378/
https://www.ncbi.nlm.nih.gov/pubmed/17558423
http://dx.doi.org/10.1038/nrmicro1709
work_keys_str_mv AT welshraymondm pathogenicepitopesheterologousimmunityandvaccinedesign
AT fujinamiroberts pathogenicepitopesheterologousimmunityandvaccinedesign

Ejemplares similares